
NASDAQ: KOD
KODIAK.COM
KODIAK
THE OPHTHALMOLOGY MEDICINES COMPANY
First Quarter 2020 Business Highlights
May 12, 2020

SPECIAL NOTE REGARDING

FORWARD-LOOKING STATEMENTS

These slides and the accompanying oral presentation contain forward-looking statements and information. The use of words such as “may,” “might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward-looking statements. For example, all statements we make regarding the initiation, timing, progress and results of our preclinical and clinical studies and our research and development programs, our regulatory strategy, our future development plans, including 2022 Vision, our ability to advance product candidates into, and successfully complete, clinical studies, and the timing or likelihood of regulatory filings and approvals, and our expected uses of cash are forward looking. All forward-looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that we expected. These statements are also subject to a number of material risks and uncertainties that are described in our most recent quarterly report on Form 10-Q, as well as our subsequent filings with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

KODIAK SCIENCES

- First Quarter 2020 Overview
- COVID-19: Update on Ongoing Clinical Studies
- Additional Corporate Highlights
- Clinical Highlights
- 2022 Vision and Execution

THE OPHTHALMOLOGY MEDICINES COMPANY

OUR MISSION

1 TRAILBLAZING SCIENCE

Our creative and thoughtful foundation

2 GENERATION 2.0 MEDICINES

Our challenge to the status quo

3 SINGULAR FOCUS IN OPHTHALMOLOGY

Our 24 / 7 / 365

Accelerated Development Strategy



BLA: biologics license application; RVO: retinal vein occlusion; BRVO: branch RVO; CRVO: central RVO; wAMD: wet age-related macular degeneration; DME: diabetic macular edema; DR: diabetic retinopathy

We are developing KSI-301 to have a meaningfully differentiated profile in each of the 4 major retinal vascular diseases

Wet AMD

CURRENT BEST

Aflibercept
once every 2 months[1]
after 3 monthly loading doses

—

KODIAK PIVOTAL STUDY DESIGN

KSI-301
once every 3, 4 or 5 months
after 3 monthly loading doses

DAZZLE Study Now Recruiting

Diabetic Macular Edema

CURRENT BEST

Aflibercept
once every 2 months[1]
after 5 monthly doses

—

KODIAK PIVOTAL STUDY DESIGN

KSI-301
once every 2-6 months
after 3 monthly loading doses

2 Pivotal Studies Planned For 2H2020 Start

Retinal Vein Occlusion

CURRENT BEST

Aflibercept
once every month[1]

—

KODIAK PIVOTAL STUDY DESIGN

KSI-301
once every 2 months or longer
after 2 monthly loading doses

1 Pivotal Study Planned For 2H2020 Start

Non-Proliferative Diabetic Retinopathy

CURRENT BEST

Aflibercept
once every 2 months[1]
after 5 monthly doses

—

KODIAK PIVOTAL STUDY DESIGN

KSI-301
once every 4 or 6 months
no loading doses

1 Pivotal Study Planned For 2H2020 Start (initiation date dependent on COVID-19 pandemic)

1. Source: Aflibercept US Prescribing Information as of August 2019

OUR 2022 VISION

WET AMD

2021 DAZZLE top-line data (potential)
2022 BLA filing

RETINAL VEIN OCCLUSION

2022 Phase 3 top-line data
2022 BLA filing

DIABETIC MACULAR EDEMA

2022 Phase 3 top-line data
2022 BLA filing

KSI-501 anti-VEGF/IL-6

2021 IND submitted
2022 Phase 1a/1b data

KSI-601 Triplet Inhibitor for dry AMD

2022 IND submitted

DIABETIC RETINOPATHY

2022 Phase 3 top-line data (potential)
2022 BLA filing (potential)

3	**Indications submitted in BLA (wAMD, DME, RVO, potentially DR)**	**3**	**Clinical molecules**	**1**	**IND per year beginning 2021**

MILESTONES AND KSI-301 DEVELOPMENT ACCELERATION

2019

KSI-301

- ✓ Safety, efficacy, durability proof-of-concept established
- ✓ Initiation of DAZZLE wAMD pivotal study
- ✓ FDA EOP2 meeting
- ✓ $225MM royalty financing
- ✓ $317MM equity financing

2020

KSI-301

- Additional readouts of Phase 1b data
- Initiate 2 DME Phase 3 trials
- Initiate 1 RVO Phase 3 trial
- Initiate 1 DR Phase 3 trial (potential)

2021

KSI-301

- Additional readouts of Phase 1b data
- Complete enrollment in DME and RVO Phase 3 studies
- DAZZLE wAMD pivotal study readout (potential)

KSI-501

- Submit IND
- Initiate Phase 1a/1b trial

2022

KSI-301

- Submit BLA for wAMD, DME, RVO, potentially DR
- DME pivotal study readouts
- RVO pivotal study readout
- DR pivotal study readout

KSI-501

- Phase 1a/1b data in inflammatory retinal diseases
- Initiate Phase 3 trials

KSI-601 (Triplet) for dry AMD

- Submit IND

2023

KSI-301

- Potential US, EU, and China regulatory approval for wAMD, DME, RVO, and potentially DR
- Potential US, EU, and China commercial launch for wAMD, DME, RVO, and potentially DR

KSI-501

- Additional readouts of Phase 1b data

Achieved

Potential Milestones 2020-23

NASDAQ: KOD KODIAK.COM